Aggregated price index with volume information
Summary:
- Gene Therapy stocks up 2.7% on average while median return up 2.5% in a day
- Gene Therapy stocks down 0.9% on average while median return down 1.9% in a week
- Gene Therapy stocks up 56.4% on average while median return up -5.6% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $ADVM 633.0%, $CAPR 56.0%, $SLDB 41.4%, $RGNX 10.8%, $VYGR 7.3%
- 1M losers are : Losers for past month are $NTLA -12.9%, $EDIT -16.0%, $QURE -19.9%, $CRSP -21.3%, $BLUE -22.0%
- 1W winners are : Winners for past week are $SLDB 7.4%, $BMRN 4.5%, $QURE 3.4%, $SRPT 3.3%
- 1W losers are : Losers for past week are $ADVM -3.6%, $CRSP -3.8%, $MGTX -4.3%, $EDIT -6.1%, $VYGR -7.6%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 26.4%, for the past 3 months is 23.6%
In the past month for a 5 days rolling window, the highest corrrelation is 50.6%, the lowest correlation is -0.9%, the latest correlation is 15.6%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 80.2% between BLUE and RARE
The lowest correlation is -49.2% between ADVM and SLDB
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET. A live webcast of the presentation will be available on the Events page of the I
Each of these three companies are entering a new era of growth.
CRANBURY, N.J., March 26, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Aaron Ondrey, as Chief Financial Officer, and the further evolution of its corporate leadership team through key appointments with existing team members. These leadership announcements build on and expand Rocket’s preparedness for its plann
SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.
CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.
SOMERVILLE, Mass., March 25, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.
One of the leaders in the global DMD drugs market is expected to outperform